Viewing Study NCT02447003


Ignite Creation Date: 2025-12-24 @ 7:24 PM
Ignite Modification Date: 2026-02-26 @ 2:16 AM
Study NCT ID: NCT02447003
Status: COMPLETED
Last Update Posted: 2020-12-16
First Post: 2015-05-14
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD1, PD-1) View
None Programmed Death-Ligand 1 (PDL1, PD-L1) View